Dermatology

Skin cells can actively help the rabies virus multiply and pass into nearby nerve cells, explaining how even small bites or scratches, particularly from bats, can lead to infection.

A study in JAMA Dermatology found that people using an AI tool were more accurate and confident in identifying skin conditions than those using standard methods, though it did not improve their understanding of next steps for care.

A large study of more than 780,000 adolescents found that atopic dermatitis is not associated with lower academic performance on national exams in Denmark or England.

Vitiligo is a chronic autoimmune disease that affects skin pigmentation and, while not painful or contagious, requires greater attention in managed care due to its long-term nature and psychosocial impact.

The FDA has approved Icotyde as the first and only IL-23R targeted oral peptide for the treatment of moderate-to-severe plaque psoriasis.

The FDA has approved Cosentyx as the first interleukin-17A (IL-17A) inhibitor approved for pediatric hidradenitis suppurativa.

The FDA has approved Sotyktu (deucravacitinib) as the first selective TYK2 inhibitor for adults with active psoriatic arthritis.

UT Southwestern researchers found that testosterone may increase susceptibility to staph infections by activating bacterial communication pathways.

A conversation with Gil Yosipovitch, M.D., explores why itch worsens at night, how it rivals chronic pain in quality-of-life impact, and why better assessment of nighttime itch and sleep disruption is urgently needed.

Research reveals oral probiotics and synbiotics improve atopic dermatitis symptoms, while studies on other skin conditions remain limited.

Combining NB-UVB light therapy with ruxolitinib cream enhances skin repigmentation in vitiligo patients, showing promising results without safety concerns.

A recent study reveals ustekinumab outperforms adalimumab and secukinumab in drug survival for psoriasis, guiding treatment decisions for patients.

New studies from the year revealed connections between medications, environmental factors and innovative treatments for skin conditions including vitiligo and atopic dermatitis.

Winter exacerbates atopic dermatitis in children, but effective management strategies and new treatments offer hope for improved skin health and comfort.

A study reveals that vitiligo significantly impacts quality of life and mental health in Japanese patients, highlighting the need for early psychological support.

A Korean study revealed that stress, not atopic dermatitis itself, significantly impacts sleep quality in adults with the skin condition.

A recent study revealed that patients with hidradenitis suppurativa experience quicker treatment failure when switching to biosimilar adalimumab compared to the original.

Ruxolitinib cream shows promising results in repigmenting vitiligo lesions, enhancing skin appearance and quality of life with a strong safety profile.

Zoryve cream gains FDA approval for treating mild to moderate atopic dermatitis in young children, offering a safe, steroid-free solution.

A new study confirms ICD-10 code L80's high accuracy in identifying vitiligo, especially when combined with treatment data, enhancing clinical research.

Opzelura gains FDA approval as the first topical JAK inhibitor for children with atopic dermatitis, offering a steroid-free treatment option.

Povorcitinib shows promising results for hidradenitis suppurativa, offering significant lesion reduction and pain relief in recent phase 3 trials.

A recent study revealed that hidradenitis suppurativa affects 1% of the global population, highlighting significant gender disparities and the need for further research.